The Wall Street Journal reports that Genomic Health has developed the Oncotype DX colon-cancer test, a genetic screen "that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease," according to the story. A validation study of the test was presented in advance of the American Society of Clinical Oncology annual meeting.